Preclinical data reveals mechanism behind microbiome therapy
Microbiotica has revealed new data on the mechanism of action of MB310, its product in development as a treatment for ulcerative colitis (UC).
The data were shared at the Keystone Symposia ‘Human Microbiome: Diversity, Selection and Adaptation’ held 18-21 February in Banff, Canada and at the European Crohn’s and Colitis Organisation (ECCO) meeting held 19-22 February in Berlin, Germany.
MB310 has been developed as an oral capsule, dosed once daily, containing a defined consortium of eight live gut commensal bacterial strains. It is designed to deliver long-term remission to UC patients, without immunosuppression or unwanted side effects.
Data from new preclinical studies presented at the congresses demonstrated that MB310 acts via at least three independent mechanisms of action (MOA) that are central to the pathology of UC: promoting the healing of the damaged gut epithelial barrier, regulating the balance of cytokines that are inflammatory (TNF) and immune-modulatory (IL-10); and inducing a regulatory T-cell response.
This included novel data demonstrating that different strains induce regulatory T-cells by different mechanisms.
MB310 is in a Phase I study COMPOSER-1, with data readout expected by the end of 2025.
The bacterial strains in MB310 were identified by analysing clinical and microbiome data from a faecal microbiota transplant (FMT) study in UC patients carried out with collaborators at the University of Adelaide.
The results demonstrated the ability of a microbiome therapy to induce remission in UC without significant side-effects. Microbiotica‘s analysis identified the engrafting bacteria associated with clinical response, leading to the development of MB310.
Microbiotica is developing a pipeline of programmes in immuno-oncology (MB097 for advanced melanoma), and inflammatory bowel disease (MB310 for ulcerative colitis).
Diana Spencer, Senior Digital Content Editor, DDW
